|Bid||0.00 x 21500|
|Ask||0.00 x 29200|
|Day's Range||5.96 - 6.53|
|52 Week Range||5.93 - 18.50|
|Beta (3Y Monthly)||2.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.75|
CNBC's "Power Lunch" team discusses generic drug makers' price fixing allegations with Chester "Chip" Davis, CEO of the Association of Accessible Medicines.
DUBLIN , May 17, 2019 /CNW/ -- Endo International plc (ENDP) today announced that clinical data from a Phase 3 investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite will be presented by Lawrence Bass , M.D., a board-certified plastic surgeon with a practice in New York City . Dr. Bass will present the Phase 3 data during the Premier Global Hot Topics session, which takes place today from 1:00pm – 6:00pm (Central Time) at the New Orleans Ernest N. Morial Convention Center. The Hot Topics session is considered to be a highlight of The Aesthetic Meeting 2019, the annual meeting of the American Society for Aesthetic Plastic Surgery (The Aesthetic Society).
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)First-quarter performanceIn the first quarter, Endo International (ENDP) reported revenue of $720.41 million, a YoY (year-over-year) rise of 2.84% and $28.10 million higher
DUBLIN , May 15, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the RBC Annual Healthcare Conference in New ...
Endo (ENDP) delivered earnings and revenue surprises of 26.19% and 4.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had a loss of 8 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to 53 cents per share. The results exceeded ...
Drugmaker Endo International Plc reported a smaller quarterly loss on Thursday, as sales of its sterile injectables and branded drugs rose. Net loss narrowed to $18.6 million, or 8 cents per share, for ...
(Reuters) - Drugmaker Endo International Plc reported a first-quarter profit that beat analysts' estimates on Thursday, helped by growing sales of its drug Xiaflex and higher revenue at its sterile injectables ...
DUBLIN , May 9, 2019 /PRNewswire/ -- First-quarter 2019 revenues increased 3 percent to $720 million compared to first-quarter 2018 revenues of $701 million First-quarter 2019 Sterile Injectables revenues ...
BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.
Endo International PLC NASDAQ/NGS:ENDPView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ENDP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.17 billion over the last one-month into ETFs that hold ENDP are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product